Share

April 24, 2012; 78 (17) Special Articles

Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]

Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

S. Holland, S.D. Silberstein, F. Freitag, D.W. Dodick, C. Argoff, E. Ashman
First published April 23, 2012, DOI: https://doi.org/10.1212/WNL.0b013e3182535d0c
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
44888

Share

RATIONALE FOR RETIREMENT

The 2012 AAN guideline “Evidence-based guideline update: NSAIDS and other complementary treatments for episodic migraine prevention in adults” has been retired by the AAN Board of Directors on September 16, 2015, due to serious safety concerns with a preventative treatment, butterbur, recommended by this guideline. The recommendations and conclusions in all retired guidelines are considered no longer valid and no longer supported by the AAN. Retired guidelines will remain available on our website for reference use only. If you would like more information on this guideline or the guideline process, please email guidelines{at}aan.com.

View Abstract

Disputes & Debates: Rapid online correspondence

  • Response to Dr. Mauskopf
    • Starr Holland, Armstrong Atlantic State University, Savannah, GA
    • Stephen D. Silberstein, Philadelphia, PA; Frederick Freitag, Dallas, TX; David W. Dodick, Scottsdale, AZ; Charles Argoff, Albany, NY
    Submitted August 28, 2012
  • Safety of Petasites (butterbur)
    • Alexander Mauskop, Director, New York Headache Center
    • New York, NY
    Submitted July 25, 2012
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

More Online

CME Course

Related Articles

Topics Discussed

Alert Me